An artificial intelligence algorithm for co‐clustering to help in pharmacovigilance before and during the COVID‐19 pandemic
- 8 February 2024
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (5) , 1258-1267
Abstract
Aims: Monitoring drug safety in real‐world settings is the primary aim of pharmacovigilance. Frequent adverse drug reactions (ADRs) are usually identified during drug development. Rare ones are mostly characterized through post‐marketing scrutiny, increasingly with the use of data mining and disproportionality approaches, which lead to new drug safety signals. Nonetheless, waves of excessive numbers of reports, often stirred up by social media, may overwhelm and distort this process, as observed recently with levothyroxine or COVID‐19 vaccines. As human resources become rarer in the field of pharmacovigilance, we aimed to evaluate the performance of an unsupervised co‐clustering method to help the monitoring of drug safety.Methods: A dynamic latent block model (dLBM), based on a time‐dependent co‐clustering generative method, was used to summarize all regional ADR reports (n = 45 269) issued between 1 January 2012 and 28 February 2022. After analysis of their intra and extra interrelationships, all reports were grouped into different cluster types (time, drug, ADR).Results: Our model clustered all reports in 10 time, 10 ADR and 9 drug collections. Based on such clustering, three prominent societal problems were detected, subsequent to public health concerns about drug safety, including a prominent media hype about the perceived safety of COVID‐19 vaccines. The dLBM also highlighted some specific drug–ADR relationships, such as the association between antiplatelets, anticoagulants and bleeding.Conclusions: Co‐clustering and dLBM appear as promising tools to explore large pharmacovigilance databases. They allow, ‘unsupervisedly’, the detection, exploration and strengthening of safety signals, facilitating the analysis of massive upsurges of reports.Keywords
This publication has 22 references indexed in Scilit:
- Consensus clustering for case series identification and adverse event profiles in pharmacovigilanceArtificial Intelligence in Medicine, 2021
- TEDAR: Temporal dynamic signal detection of adverse reactionsArtificial Intelligence in Medicine, 2021
- Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug ReactionsClinical Pharmacology & Therapeutics, 2021
- Global COVID‐19 pandemic and reporting behavior ‐ An analysis of the Food and Drug Administration adverse events reporting systemPharmacoepidemiology and Drug Safety, 2021
- Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problemInternational Journal of Cardiology, 2021
- Impact of the “French Levothyrox crisis” on signal detection in the World Health Organization pharmacovigilance databasePharmacoepidemiology and Drug Safety, 2018
- Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case ProcessingClinical Pharmacology & Therapeutics, 2018
- Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial FibrillationChest, 2016
- Outlier removal to uncover patterns in adverse drug reaction surveillance – a simple unmasking strategyPharmacoepidemiology and Drug Safety, 2013
- A Bayesian neural network method for adverse drug reaction signal generationEuropean Journal of Clinical Pharmacology, 1998